Benzinga Exclusives

EXCLUSIVE: Intelligent Bio Solutions Q3 Gross Profit Jumps By 91%

Intelligent Bio Solutions reported a Q3 loss of 44 cents per share with a 20% revenue rise from Q2 and 91% year-over-year gross profit growth.

EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants

Alzamend Neuro starts Phase 2 trial of AL001 with novel coil tech to test improved lithium delivery in the brain for multiple mental health conditions.

Tech Traders Are Speed-Dating Volatility And Palantir Is The Perfect Case Study

Traders are swiping right on volatility, using leveraged ETFs to play quick moves. Palantir's earnings highlight split sentiment in tech. Valuations and growth are under scrutiny.

EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients

Lantern Pharma receives FDA clearance to begin Phase 1b/2 trial of LP-184 in advanced NSCLC patients with key mutations and low PD-L1 expression.

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell